Reviewing the role of donepezil in the treatment of Alzheimer's disease

Rachelle S. Doody, Jeffrey L. Cummings, Martin Farlow

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Donepezil is a reversible, non-competitive piperidine-type acetylcholinesterase inhibitor (AChEI) that is structurally unique compared with other currently available AChEIs. It was developed as a symptomatic treatment to compensate for the progressive loss of cholinergic signal between neurons, a consequence of neuronal cell loss in the brains of patients with Alzheimer's disease (AD). Clinical trials conducted over the 15 years since the drug was first licensed and available for use in patients with mild to moderate AD (1997) have shown that donepezil is efficacious and well tolerated at all stages of AD, from patients with mild or moderate impairment to those with severe disease. The published literature contains nearly 2000 papers on donepezil, and more than 200 of these articles relate to randomized controlled clinical trials. Trials in patients with mild cognitive impairment (MCI) failed to meet all of their primary objectives, but provided insights into patient selection and the design of trials. Overall, more than a decade of donepezil research has gradually changed attitudes toward therapy of AD from a general belief that no clinically useful treatment exists to the present day understanding that symptomatic therapy may be effective across the spectrum of dementia stages.

Original languageEnglish
Pages (from-to)773-781
Number of pages9
JournalCurrent Alzheimer Research
Volume9
Issue number7
DOIs
StatePublished - 2012

Fingerprint

Alzheimer Disease
Cholinesterase Inhibitors
Therapeutics
Cholinergic Agents
Patient Selection
Dementia
Randomized Controlled Trials
Clinical Trials
Neurons
donepezil
Brain
Research
Pharmaceutical Preparations

Keywords

  • Acetylcholinesterase inhibitor
  • Alzheimer's disease
  • Donepezil
  • Mild cognitive impairment
  • Mild to moderate Alzheimer's disease
  • Moderate severe to severe Alzheimer's disease

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Reviewing the role of donepezil in the treatment of Alzheimer's disease. / Doody, Rachelle S.; Cummings, Jeffrey L.; Farlow, Martin.

In: Current Alzheimer Research, Vol. 9, No. 7, 2012, p. 773-781.

Research output: Contribution to journalArticle

Doody, Rachelle S. ; Cummings, Jeffrey L. ; Farlow, Martin. / Reviewing the role of donepezil in the treatment of Alzheimer's disease. In: Current Alzheimer Research. 2012 ; Vol. 9, No. 7. pp. 773-781.
@article{14ec9689a5ae4bdbadbe07ba0a3a3adf,
title = "Reviewing the role of donepezil in the treatment of Alzheimer's disease",
abstract = "Donepezil is a reversible, non-competitive piperidine-type acetylcholinesterase inhibitor (AChEI) that is structurally unique compared with other currently available AChEIs. It was developed as a symptomatic treatment to compensate for the progressive loss of cholinergic signal between neurons, a consequence of neuronal cell loss in the brains of patients with Alzheimer's disease (AD). Clinical trials conducted over the 15 years since the drug was first licensed and available for use in patients with mild to moderate AD (1997) have shown that donepezil is efficacious and well tolerated at all stages of AD, from patients with mild or moderate impairment to those with severe disease. The published literature contains nearly 2000 papers on donepezil, and more than 200 of these articles relate to randomized controlled clinical trials. Trials in patients with mild cognitive impairment (MCI) failed to meet all of their primary objectives, but provided insights into patient selection and the design of trials. Overall, more than a decade of donepezil research has gradually changed attitudes toward therapy of AD from a general belief that no clinically useful treatment exists to the present day understanding that symptomatic therapy may be effective across the spectrum of dementia stages.",
keywords = "Acetylcholinesterase inhibitor, Alzheimer's disease, Donepezil, Mild cognitive impairment, Mild to moderate Alzheimer's disease, Moderate severe to severe Alzheimer's disease",
author = "Doody, {Rachelle S.} and Cummings, {Jeffrey L.} and Martin Farlow",
year = "2012",
doi = "10.2174/156720512802455412",
language = "English",
volume = "9",
pages = "773--781",
journal = "Current Alzheimer Research",
issn = "1567-2050",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Reviewing the role of donepezil in the treatment of Alzheimer's disease

AU - Doody, Rachelle S.

AU - Cummings, Jeffrey L.

AU - Farlow, Martin

PY - 2012

Y1 - 2012

N2 - Donepezil is a reversible, non-competitive piperidine-type acetylcholinesterase inhibitor (AChEI) that is structurally unique compared with other currently available AChEIs. It was developed as a symptomatic treatment to compensate for the progressive loss of cholinergic signal between neurons, a consequence of neuronal cell loss in the brains of patients with Alzheimer's disease (AD). Clinical trials conducted over the 15 years since the drug was first licensed and available for use in patients with mild to moderate AD (1997) have shown that donepezil is efficacious and well tolerated at all stages of AD, from patients with mild or moderate impairment to those with severe disease. The published literature contains nearly 2000 papers on donepezil, and more than 200 of these articles relate to randomized controlled clinical trials. Trials in patients with mild cognitive impairment (MCI) failed to meet all of their primary objectives, but provided insights into patient selection and the design of trials. Overall, more than a decade of donepezil research has gradually changed attitudes toward therapy of AD from a general belief that no clinically useful treatment exists to the present day understanding that symptomatic therapy may be effective across the spectrum of dementia stages.

AB - Donepezil is a reversible, non-competitive piperidine-type acetylcholinesterase inhibitor (AChEI) that is structurally unique compared with other currently available AChEIs. It was developed as a symptomatic treatment to compensate for the progressive loss of cholinergic signal between neurons, a consequence of neuronal cell loss in the brains of patients with Alzheimer's disease (AD). Clinical trials conducted over the 15 years since the drug was first licensed and available for use in patients with mild to moderate AD (1997) have shown that donepezil is efficacious and well tolerated at all stages of AD, from patients with mild or moderate impairment to those with severe disease. The published literature contains nearly 2000 papers on donepezil, and more than 200 of these articles relate to randomized controlled clinical trials. Trials in patients with mild cognitive impairment (MCI) failed to meet all of their primary objectives, but provided insights into patient selection and the design of trials. Overall, more than a decade of donepezil research has gradually changed attitudes toward therapy of AD from a general belief that no clinically useful treatment exists to the present day understanding that symptomatic therapy may be effective across the spectrum of dementia stages.

KW - Acetylcholinesterase inhibitor

KW - Alzheimer's disease

KW - Donepezil

KW - Mild cognitive impairment

KW - Mild to moderate Alzheimer's disease

KW - Moderate severe to severe Alzheimer's disease

UR - http://www.scopus.com/inward/record.url?scp=84866669849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866669849&partnerID=8YFLogxK

U2 - 10.2174/156720512802455412

DO - 10.2174/156720512802455412

M3 - Article

C2 - 22175653

AN - SCOPUS:84866669849

VL - 9

SP - 773

EP - 781

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1567-2050

IS - 7

ER -